Secondary primary malignancies after CD‐19 directed CAR‐T‐cell therapy in lymphomas: A report from the Italian CART‐SIE study

Documenti analoghi

• Brexucabtagene autoleucel in‐vivo expansion and BTKi refractoriness have a negative influence on progression‐free survival in mantle cell lymphoma: Results from CART‐SIE study
  di: Federico Stella, et al.
  Pubblicazione: (2024)
• 350 | PATIENTS WITH RELAPSED/REFRACTORY PMBCL HAVE BETTER SURVIVAL WHEN THE SALVAGE STRATEGY INCLUDES CAR T‐CELLS: AN ANALYSIS OF THE REPRIME‐FIL AND THE CART‐SIE STUDIES
  di: A. Guidetti, et al.
  Pubblicazione: (2025)
• Occult hepatitis B virus infection status is not associated with impaired efficacy of anti‐CD19 CAR‐T‐cell therapy for lymphoma and shows a distinct immune toxicity profile: Results from the CART‐SIE study
  di: Nicola Polverelli, et al.
  Pubblicazione: (2026)
• J. A. Millward (1998). Beyond the pass: Economy, ethnicity, and empire in Qing Central Asia, 1759-1864. Stanford: Stanford University Press
  di: Chiara Olivieri
  Pubblicazione: (2018)
• J. Leibold (2007). Reconfiguring Chinese nationalism: How the Qing frontier and its indigenes became Chinese. Nueva York: Palgrave MacMillan. 271 pp.
  di: Chiara Olivieri
  Pubblicazione: (2019)